Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

•Quality of life was assessed in 26 XLH patients before and after 4 months of treatment with KRN23.•All mean scores showed a trend of improved health after 4 doses of KRN23 treatment.•Role limitations due to physical health was significantly improved after multiplicity correction.•Patient reported o...

Full description

Bibliographic Details
Main Authors: Ruppe, Mary D., Zhang, Xiaoping, Imel, Erik A., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey S., Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Peacock, Munro, Carpenter, Thomas O.
Format: Online
Language:English
Published: Elsevier 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/

Similar Items